Share
A blood report full of arrows and highlighted numbers can be worrying. During chemotherapy, a result outside the laboratory range does not automatically mean something has gone wrong. Equally, a recent normal result does not make a new symptom safe to ignore.
Your team looks at the trend, the timing of your last treatment and how you feel. The useful question is not simply “Is this normal?” but “What does this mean for my next treatment and what should I do now?”
When to seek help without waiting for a report
During chemotherapy, a temperature of 38°C (100.4°F) or above needs an immediate call to your treating team or urgent assessment. Follow a lower temperature threshold if your unit has given one. Do not wait for a repeat blood count, the next appointment or a reply to a routine message.
Feeling suddenly very unwell, shaking chills, confusion, new breathing difficulty, chest pain, fainting or bleeding that will not stop also need urgent medical help, even without a fever. If you cannot promptly reach your team, go to the nearest emergency department and say that you are receiving chemotherapy.
Keep your unit’s emergency number and treatment details available. Do not take fever-reducing medicine just to hide a temperature and wait at home.
Why blood tests are checked during treatment
Chemotherapy can affect the bone marrow, where blood cells are made. Kidney and liver results also help the team assess how treatment is being handled and whether a dose needs to change.
Tests are commonly checked before a cycle or a scheduled dose, and sometimes between treatments. The timing and panel depend on your regimen. Ask when your sample should be taken and who will confirm that the results have been reviewed.
Blood counts mainly help assess treatment safety. They do not, by themselves, show whether the tumour is shrinking. That question may need examination, scans or other tests.
Read the units as well as the number
Look at the test name, result, unit, laboratory reference range and previous results together. The reference range is not the same as the threshold for giving your chemotherapy. Those thresholds vary with the medicines, treatment aim and your situation.
Indian reports may use cells per microlitre (µL), cells per cubic millimetre (cumm), or ×10⁹/L. For example, platelets of 150 ×10⁹/L equal 150,000 per µL, also written as 1.5 lakh per µL. These are unit examples, not a target you need to reach.
Ask for help with conversions rather than comparing two numbers in different units. Send the complete dated report, with your identifying details visible, through the channel your team has agreed. A cropped photograph of one abnormal value can leave out important context.
Haemoglobin: oxygen delivery and anaemia
Haemoglobin, often labelled Hb, is the oxygen-carrying protein in red blood cells. A low level is called anaemia. It can contribute to tiredness, breathlessness, dizziness or a faster heartbeat, although these symptoms can have other causes too.
Chemotherapy is one possible cause. Bleeding, the cancer, kidney problems or a lack of iron, vitamin B12 or folate may also contribute. Treatment depends on the cause, symptoms and severity; some people need a transfusion.
Do not start iron tablets or tonics just because haemoglobin is low. Ask whether a deficiency has been established. New chest pain, severe breathlessness or fainting needs urgent assessment rather than waiting for the haemoglobin to improve.
White cells and the absolute neutrophil count
White blood cells help defend against infection. Neutrophils are one type. A low neutrophil count is called neutropenia; the absolute neutrophil count (ANC) is often more useful for assessing infection risk than the total white-cell count alone.
ANC may be printed directly, or the team may interpret it from the white-cell differential. A percentage alone is not the absolute count. Ask which result your unit uses rather than trying to decide treatment eligibility yourself.
The nadir is the lowest point after a treatment. It often occurs in the following one to two weeks, but timing and recovery vary considerably between regimens. There is no universally safe day based only on the calendar. You can feel well with a low count, and infection can develop after a reassuring earlier test.
Platelets: bruising and bleeding
Platelets help blood clot. Low platelets, called thrombocytopenia, may cause easy bruising, tiny red or purple skin spots, nosebleeds or bleeding gums. Tell your team about new bleeding or unusual bruising.
Bleeding that will not stop, blood in vomit or stools, black tarry stools, or a new severe headache needs urgent assessment. Your team may recommend a treatment adjustment or, in some situations, a platelet transfusion.
Ask before taking aspirin, ibuprofen or herbal products that may affect bleeding. If you already take a prescribed blood thinner or aspirin, contact the prescriber for instructions rather than stopping it yourself.
Kidney, liver and electrolyte results
Creatinine and an estimated glomerular filtration rate (eGFR) help assess kidney function. Kidney results are sometimes grouped as KFT or RFT. The dose of some medicines depends on kidney function, but the calculation used is treatment-specific.
Liver tests may include bilirubin, ALT and AST, sometimes labelled SGPT and SGOT. An abnormal result can have several causes; it does not automatically mean that cancer has spread to the liver. Your team compares it with earlier results, symptoms and medicines.
Sodium, potassium, magnesium and calcium are examples of electrolytes or minerals that may be checked. Treatment, vomiting, diarrhoea and dehydration can alter them. Do not start supplements or change fluid intake solely from an online calculator; replacement and fluid advice need to fit your kidney function and other conditions.
Why a cycle may be delayed or the dose changed
If the risk from the next dose is too high, the team may allow more recovery time, repeat tests, adjust the dose or change supportive treatment. Infection, organ function and side effects matter as well as the blood count.
A delay does not mean that treatment has failed or that you have done something wrong. Its importance depends on the cancer, treatment aim, length of delay and how often it happens. Your team balances timely treatment with safe recovery; ask how a delay affects your particular plan.
Ask which result led to the decision, when it will be rechecked and what the plan is if recovery takes longer. Do not move or restart cancer tablets yourself because the report looks better.
What can help blood counts recover?
Granulocyte colony-stimulating factor (G-CSF), such as filgrastim or pegfilgrastim, helps the marrow produce neutrophils. It is prescribed for selected treatments and situations. It does not correct every low blood count, and it does not replace urgent assessment of a fever.
Follow the exact injection schedule and ask how to manage side effects such as bone pain. Do not add, omit or shift an injection without checking.
Eating enough and treating a proven deficiency support health, but food or juice cannot reliably reverse chemotherapy-related marrow suppression. Papaya-leaf products have limited evidence and are not an established substitute for treatment of low counts during chemotherapy. Supplements can cause adverse effects or interactions; discuss them before use.
Can erythropoietin help a low haemoglobin?
Erythropoietin-type medicines, such as epoetin alfa and darbepoetin, help the marrow make red blood cells and can reduce transfusion needs. For chemotherapy-related anaemia, ASCO/ASH guidance supports selected use when treatment is not intended to cure the cancer and haemoglobin is below 10 g/dL. They should not be used for chemotherapy-related anaemia when treatment aims to cure. The team first checks other causes, including iron deficiency. These medicines act gradually, increase blood-clot risk and have been linked to worse cancer outcomes in some settings. They are not a substitute for an urgently needed transfusion.
Can romiplostim help a persistently low platelet count?
Romiplostim helps the marrow produce platelets. An oncologist may consider it when chemotherapy-related low platelets persist and disrupt treatment, after checking other causes. A 2026 trial in people receiving oxaliplatin-based treatment for gastrointestinal cancers found fewer chemotherapy delays or dose changes caused by low platelets. This does not establish a survival benefit or suitability for every cancer or regimen. Use for chemotherapy-related low platelets may be off-label: your team should explain the local approval status, expected benefit, monitoring and risks, including blood clots. It does not replace urgent assessment or a platelet transfusion when needed for bleeding.
A short checklist for each cycle
- When should I have the tests, and has someone reviewed the complete report?
- Which results matter for this treatment, and how have they changed?
- If treatment is postponed, what is the new test and treatment plan?
- Do any medicines, injections or precautions change?
- What temperature or symptoms should prompt an immediate call, and which number should I use?
Common questions
My count is low but I feel well. Can treatment go ahead?
Sometimes it can, sometimes it cannot. Feeling well does not measure infection or bleeding risk. Your team decides using the exact result, regimen and clinical situation.
Should I repeat an unexpected result at another laboratory?
Contact the team first. Occasionally a sample problem or an unexpected result needs confirmation, but arranging repeated tests on your own can delay the right action.
Can I wait until morning if I develop a fever?
No. During chemotherapy, follow your emergency plan immediately. A recent normal blood count does not rule out a serious infection.
Sources and further reading
- Cancer Research UK: Tests before and during chemotherapy
- Macmillan Cancer Support: Blood tests
- American Cancer Society: Neutropenia
- OncoLink, Penn Medicine: Neutropenic fever
- American Cancer Society: Anaemia
- American Cancer Society: Low platelet counts
- Cancer Research UK: Changing your chemotherapy plan
- Cancer Research UK: G-CSF
- Memorial Sloan Kettering Cancer Center: Papaya leaf
- ASCO/ASH: Management of cancer-associated anaemia with erythropoiesis-stimulating agents (2019)
- MedlinePlus: Epoetin alfa—uses and important warnings
- Al-Samkari and colleagues: Romiplostim for chemotherapy-induced thrombocytopenia—RECITE trial, New England Journal of Medicine (2026)
- Nplate (romiplostim): US prescribing information—approved uses and safety precautions
Medically reviewed and approved by Dr (Prof) Vijay Agarwal
Professor and Lead Consultant – Medical Oncology
